Ongoing, recruitingPhase I and Phase II (Integrated)- OtherInterventional

A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)

At a glance

Status

Ongoing, recruiting

Phase

Phase I and Phase II (Integrated)- Other

Sponsor

F. Hoffmann-La Roche AG

Enrolment target

Start

25 Oct 2023

MPR rate

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.